NuvOx welcomes all inquiries regarding potential opportunities for collaboration or investment. Please e-mail your inquiries to John McGonigle, Business Development Associate, at jmcgonigle@nuvoxpharma.com  

pipeline partnership at NuvOx Pharma


  1. In stroke, animal studies show that DDFPe can reduce neurological damage by 85%. A randomized, placebo controlled Phase Ib/II clinical trial is being supported by the University of Arkansas for Medical Sciences. The FDA has allowed an IND for an open-label Phase II clinical trial.
  2. In oncology, DDFPe is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation, chemotherapy, and/or immunotherapy. It has completed enrollment in a Phase Ib/II clinical trial in glioblastoma multiforme patients receiving radiation therapy and chemotherapy. The trial showed statistically significant evidence of tumor re-oxygenation (p=0.015) with no significant change in the oxygenation of the normally oxygenated brain tissue (p=0.65). Early results show evidence of increased overall survival. The FDA has allowed an Investigational New Drug application for a Phase II clinical trial.
  3. In sickle cell crisis, a pre-clinical study of acute chest syndrome in mice saw 0% survival in controls and 100% survival in treated animals. The FDA has allowed a Phase Ib clinical trial in collaboration with the University of Pittsburgh.
  4. In myocardial infarction, studies in mice show that DDFPe can reduce the damage to cardiac tissue from myocardial infarction by 72% when DDFPe is given after myocardial infarction is induced. NuvOx has recently received funding from the NHLBI to study the effects of DDFPe in a porcine model of myocardial infarction.
  5. In hemorrhagic shock, studies by the US Army showed 0% survival in controls and 100% survival in treated animals. NuvOx has partnered with Jiangsu Nhwa Pharmaceutical Co., Ltd., to develop the product in China – NuvOx retains rights in the rest of the world for treatment of hemorrhagic shock.
  6. In traumatic brain injury (TBI), animal studies by the US Navy showed an increase in brain tissue oxygen tension with DDFPe administration following TBI in rats.

Leave a Reply

Your email address will not be published.